Raxibacumab

Type: Product

Name: Raxibacumab

First Reported Nov 18 2009 - Updated Nov 18 2009 - 1 Documents

Food and Drug Administration

US FDA seeks additional information from HGS's raxibacumab BLA

Human Genome Sciences, Inc (HGS) has received a Complete Response Letter from the US Food and Drug Administration (FDA) relating to the company's Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational ... [Published Nov 18 2009 by PharmaBiz]

Entities: Food and Drug Administration, Anthrax, complete response, Toxin, Bacteria

Quotes

"The HGS financial position was significantly strengthened during 2009," said Tim Barabe, Senior Vice President and Chief Financial Officer. "With the proceeds from two successful public offerings of HGSI common stock, our cash position is more than sufficient to take us through the filing of marketing applications and the launch of our late-stage products, while also continuing to enable investment in our earlier-stage pipeline. Excluding $813 million in new funding, we realized net cash flow of nearly $30 million in 2009."

Human Genome Sciences Reports 4Q and Full-Year 2009 Financial Res... [Zibb - Mar 04 2010]

More Content

sort by: Date \| Relevance
Human Genome Sciences Reports 4Q and Full-Year ... [Zibb - Mar 04 2010]
Human Genome Sciences Reports 4Q and Full-Year ... [TradingMarkets - Mar 04 2010]
Human Genome Sciences Announces Fourth-Quarter ... [Forbes.com - Mar 02 2010]
Human Genome Sciences Announces Fourth-Quarter ... [Street Insider - Mar 02 2010]
Human Genome Sciences Announces Fourth-Quarter ... [Stockwatch - Mar 02 2010]
US FDA seeks additional information from HGS's ... [PharmaBiz - Nov 18 2009]
UPDATE 1-Human Genome gets new order for anthra... [Reuters - Jul 22 2009]

Blogs

sort by: Date \| Relevance
BioMed News Bytes: Dyax, Human Genome Sciences,... [IPO Analysis from Seeking Alpha - Oct 29 2009] Mike Havrilla submits:The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical ...
BioMed News Bytes: Dyax, Human Genome Sciences,... [Healthcare Sector and Stocks Analysis from Seek ... - Oct 29 2009] Mike Havrilla submits:The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical ...
BioMed News Bytes: Dyax, Human Genome Sciences,... [Biotech Sector and Stocks Analysis from Seeking ... - Oct 29 2009] Mike Havrilla submits:The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical ...